CB1 Blockade Reduced Selected Morphine Withdrawal Signs Without Preventing Analgesic Tolerance in Rats
Chronic CB1 receptor blockade reduced some naloxone-precipitated morphine withdrawal signs in rats without preventing tolerance to morphine's analgesic effect. The two findings came from the same 2000 study and should be reported together.
The experiment separated tolerance from withdrawal
Rats received morphine pellets and repeated SR141716A, a CB1 receptor antagonist. The investigators examined tolerance to a morphine analgesic effect and separately challenged the animals with naloxone to precipitate opioid withdrawal. That challenge design does not reproduce spontaneous discontinuation, and the intervention was CB1 blockade rather than THC or a cannabis product.
Withdrawal effects were selective
The abstract reports significant reductions in digging, teeth chattering, penile licking and diarrhea. Other observed signs, including writhing, head shakes and rearing, were unaffected. Summarizing this as complete prevention of withdrawal would discard those null findings. The result was a change in selected measured manifestations of an experimentally precipitated syndrome.
Analgesic tolerance did not follow the same pattern
The chronic antagonist regimen did not influence development of tolerance to morphine's analgesic effect in this study. A reduction in withdrawal intensity therefore cannot be substituted for evidence that morphine retained its initial analgesic effectiveness. Adaptation to repeated treatment and the response to an antagonist challenge were separable outcomes under these experimental conditions.
Interpreting the evidence
The study provides preclinical evidence that manipulating cannabinoid signaling can affect selected opioid-withdrawal signs independently of analgesic tolerance. It does not establish effectiveness or safety in people, and it does not support treating opioid withdrawal with an untested cannabis product.
Related reading: THC findings in a different opioid-withdrawal model.
Research reference
Rubino T; Massi P; Viganò D; et al. (2000). Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome. Life sciences. doi:10.1016/s0024-3205(00)00547-6. Evidence basis: study abstract.
